Category: Regulatory DisclosuresBy adminJune 20, 2022 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. commences the production of antiviral COVID-19 treatment, Molnupiravir RamedaNextNext post:Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. joins the UN Global Compact, the world’s largest corporate sustainability initiative.Related PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024
